Screener
Revolution Medicines, Inc. RVMD Operating Lease Liabilities
Operating Lease Liabilities at other companies
Other financials
Where this comes from
Reported directly by Revolution Medicines, Inc. in its filing.
Tagged under the XBRL concept us-gaap:OperatingLeaseLiabilityNoncurrent.
The source filing: Revolution Medicines, Inc.’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 4:10 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-335104
| Line item | June 30, 2026 | December 31, 2025 |
|---|---|---|
| Operating lease liability, current | 16,753 | 16,468 |
| Total current liabilities | 354,061 | 290,424 |
| Deferred tax liability | 2,353 | 2,353 |
| Operating lease liability, noncurrent | 137,741 | 142,234 |
| Liability related to the sale of future royalties | 548,542 | 268,446 |
| Convertible senior notes, noncurrent | 487,434 | — |
| Warrant liability | 185,253 | 18,546 |
| Other noncurrent liabilities | 1,648 | 1,208 |
Item 1. Financial Statements.
FAQ
- What is Revolution Medicines, Inc.'s operating lease liabilities?
- Revolution Medicines, Inc. (RVMD) reported operating lease liabilities of $137.74M in Q2 2026.
- How has Revolution Medicines, Inc.'s operating lease liabilities changed year-over-year?
- Revolution Medicines, Inc.'s operating lease liabilities increased by 15.1% year-over-year, from $119.7M to $137.74M.
- What is the long-term trend for Revolution Medicines, Inc.'s operating lease liabilities?
- Over 5 years (2020 to 2025), Revolution Medicines, Inc.'s operating lease liabilities has grown at a 37.5% compound annual growth rate (CAGR), from $28.99M to $142.23M.
- What does operating lease liabilities mean?
- Long-term portion of operating lease obligations extending beyond one year, representing committed future rent payments.
Ask your AI about Revolution Medicines, Inc.'s operating lease liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude